Sarcoidosis is a Th1/Th17 multisystem disorder: wider implications
MedWorm Sponsor Message: Please support the DoctorsInChains.org campaign for the health workers in Bahrain. #FreeDoctors
MedWorm Sponsor Message: Please support the DoctorsInChains.org campaign for the health workers in Bahrain. #FreeDoctors
MedWorm Sponsor Message: Please support the DoctorsInChains.org campaign for the health workers in Bahrain. #FreeDoctors
Patients with advanced lung cancer experience a high symptom burden with great impact upon functional status and quality of life and poor long-term survival.
Respiratory symptoms, like dyspnea, cough, and hemoptysis, are highly prevalent and cause profound distress at the time of diagnosis and as disease progresses.
This review discusses common reversible causes of dyspnea and examines pharmacologic and nonpharmacologic approaches to symptom management of dyspnea, cough, and hemoptysis.
When considering surgical treatment for non-small-cell lung cancer (NSCLC), a distinction is made between early-stage disease (stages IA/B and IIA/B), locoregionally advanced disease (stages IIIA/B) and metastatic disease (stage IV). Complete surgical resection of NSCLC can provide good long-term outcome.
Surgery is considered the treatment of choice in patients with early-stage NSCLC or patients with T3N1 disease. Surgery for locoregionally advanced disease remains controversial. In specific cases of T4 disease, surgery can provide long-term survival. In patients with stage IIIA-N2 disease, surgery is only offered to patients who have achieved mediastinal downstaging following induction therapy.
Careful preoperative evaluation is clearly important in the staging and selection of patients with NSCLC for surgery.